Elicera Therapeutics (ELIC) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
14 Oct, 2026Presentation and Q&A
Video interview published with Jamal El-Mosleh and Di Yu, covering the CAR-T field and positioning within it.
Questions addressed operations, continued commercialization and the forthcoming rights issue.
Pipeline and platform
Four drug candidates in development: two CAR T-cell therapies and two oncolytic viruses.
Commercially available iTANK platform can enhance CAR T-cell effects and activate killer T cells against cancer; licensing is offered to CAR T developers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Elicera Therapeutics
- ELC-301 delivered CMR in 8/12 patients, with CARMA Phase IIa recruitment expected in Q4 2026.ELIC
Study update - Investor events set for March 4–5, with a four-candidate pipeline and iTANK platform.ELICInvestor Update
- Strong clinical results and new funding support continued pipeline progress in cell therapy.ELICQ2 2026
- Losses widened, cash burn increased, and new financing and collaborations advanced the pipeline.ELICQ2 2024
- Improved Q1 results and robust clinical advances, with strong CARMA study outcomes.ELICQ1 2026
- Promising clinical results and stable cash position despite increased losses in 2025.ELICQ4 2025
- Returned to operating profit in Q3 2025 with strong clinical and financial progress.ELICQ3 2025
- Improved financials, strong CARMA study results, and funding secured through mid-2027.ELICQ2 2025
- Q3 loss narrowed, clinical milestones reached, and rights issue strengthened liquidity.ELICQ3 2024